Market Place
Sourcing Support
Optime Care Expands Partnership With Rigel For Tavalisse Distribution
16 Oct 2024 //
GLOBENEWSWIRE
Annora Pharma`s Generics Fostamatinib Receives Approval in US
23 Sep 2024 //
FDA
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
06 Aug 2024 //
PR NEWSWIRE
Rigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback
10 Oct 2022 //
PRNEWSWIRE
Rigel Announces Top-line Results from FORWARD PIII Trial of Fostamatinib
08 Jun 2022 //
PRNEWSWIRE
Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan
21 Dec 2021 //
PRNEWSWIRE
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
15 Nov 2021 //
PRNEWSWIRE
Fostamatinib reduces COVID-19 risks by 50 percent in Phase II study
02 Sep 2021 //
EUROPEANPHARMACEUTICALREVIEW
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib
01 Sep 2021 //
PRNEWSWIRE
FDA dismisses Rigel`s EUA; Seattle biotech to co-develop mRNA vaccine.
16 Aug 2021 //
ENDPTS
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
29 Jun 2021 //
PRESS RELEASE
Rigel Announces Completion of Patient Enrollment for NIH/NHLBI- Ph2 Trial
11 Mar 2021 //
PRNEWSWIRE
Enrollment underway for Rigel Pharma`s fostamatinib in mid-stage COVID-19 study
09 Oct 2020 //
SEEKINGALPHA
Fostamatinib in chronic immune thrombocytopenia: Added benefit is not proven
06 Oct 2020 //
MEDICAL EXPRESS
NIH launches trial of Rigel drug for severe COVID-19
17 Sep 2020 //
REUTERS
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in COVID-19 Patients
17 Sep 2020 //
BIOSPACE
Rigel to Present at the Jefferies Virtual Healthcare Conference
26 May 2020 //
PR NEWSWIRE
Rigel`s fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharma
23 Sep 2019 //
PR NEWSWIRE
TAVALISSE™ fostamatinib disodium hexahydrate ph3 Data Published
30 Apr 2018 //
PR NEWSWIRE
Rigel snags first FDA win with Tavalisse OK
18 Apr 2018 //
FIERCE PHARMA
Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate)
17 Apr 2018 //
PR NEWSWIRE
Rigel hit with another trial setback as lead drug fostamatinib fails PhII
04 Apr 2018 //
ENDPTS
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.